Actavis Allergan Valeant

Valeant to raise Allergan bid by $4.5 billion

Published: 04:33, October 8, 2014

Canadian firm Valeant Pharmaceuticals International Inc. with activist investor William Ackman plan to raise their hostile offer for Allergan Inc. by $4.5 billion, which would value the Botox maker at more than $56 billion, according to several newspapers which quoted unnamed people familiar with the matter.

If the deal goes through, something the Allergan board is trying to prevent with all its might, it would be the biggest pharmaceutical industry deal in 2014, exceeding AbbVie’s takeover of Shire for $54 billion.

Valeant and Mr. Ackman’s Pershing Square Capital Management LP are said to be considering a higher offer if a rival bidder emerges before December’s shareholder meeting. A prospect that is becoming more likely.

Allergan has rejected all Valeant’s offers as “grossly inadequate” and has refused to meet with the Canadian company. The Botox maker has been trying to prevent the takeover by striking a deal of its own.



On September 29, Allergan’s board of directors said in a statement:

“Our conclusion that Valeant’s offer is grossly inadequate and substantially undervalues Allergan remains unchanged. We continue to believe strongly that Valeant’s offer does not appropriately reflect the underlying value of Allergan’s assets, operations and prospects, including Allergan’s industry-leading franchises of global scale and its projected growth opportunities.”

Allergan announced in September that it was in talks to acquire Salix Pharmaceuticals. Mr. Ackman, whose company Pershing owns 9.72% of Allergan, said he would sue if an acquisition was agreed without shareholders’ approval.

Valeant Allergan Actavis

Valeant and Actavis want to buy Allergan. Allergan likes Actavis but does not like Valeant.

To Valeant’s horror, Actavis plc appears on the scene

Dublin-based Actavis plc is interested in acquiring Allergan and has been in talks with the company. Several key Allergan shareholders, however, have criticized its strategy, saying it is wrong to proceed if the only reason is to prevent a hostile takeover. When the board of directors of the target company is not happy with the acquisition, it is called a hostile takeover attempt.

Actavis has held informal talks with Allergan in recent months about a possible merger. It is now seriously considering acquiring the Irvine-based company.

People familiar with the matter say a formal approach may occur some time this week. Actavis is the third largest generics prescription drug manufacturer in the world.

Valeant and Mr. Ackman aim to replace several Allergan board members during the December 18 shareholder meeting with Valeant-friendly people.

Share prices favoring Allergan

As far as share prices are concerned, Allergan seems to be coming out better than Valeant during the prolonged takeover battle. On Monday, Allergan shares were 1.7% up at $186.20 on the NY Stock Exchange.

Valeant shares were 2.5% down on Monday, closing at $175.94 per share.

According to Valeant, its shares should rise considerably after its earnings are announced next week.

Valeant’s growth and survival are entirely dependent on acquisitions, given that the company lacks an effective research and development unit. Allergan, on the other hand, has a large R&D division and lots of cash, and could easily survive and thrive on its own.

Valeant is known as a corporate raider – a company that buys other firms and then asset strips them.


Video – What is takeover?


Veronica Salvador Avatar

Other News

Purchase-linked donations can change direct giving in a small experiment

Nov 22, 2026

Volunteer recruitment emails were followed by more donations in a nonprofit experiment

Nov 22, 2026

Customer-created content was linked to brand perceptions in a survey of Pakistani shoppers

Nov 22, 2026

Shopping games can frustrate customers when rewards and rules are hard to understand

Nov 22, 2026

Text-message business training helped Kenyan entrepreneurs briefly, but gains faded

Nov 22, 2026

Food traceability labels raised stated interest, but ad test found no clear difference

Nov 22, 2026

Letting shoppers keep an item for a partial refund lifted later spending in a field experiment

Nov 22, 2026

Skincare claims that look scientific changed shopping choices in an online experiment

Nov 21, 2026

Crowded settings can make unfamiliar products less appealing in consumer experiments

Nov 21, 2026

Words that describe texture can affect online clothing choices, study finds

Nov 21, 2026

Impact measurement support helped Indian social enterprises grow in a field experiment

Nov 21, 2026

Lyft experiment found a premium ride option shifted some customers to cheaper fares

Nov 21, 2026

Online retailer improved pricing by testing how shoppers respond to rivals

Nov 21, 2026

Environmental reminders reduced return shipments in a fashion retailer experiment

Nov 21, 2026

When a discount is hard to claim, it can reduce sales of the product

Nov 20, 2026

A small step to claim a discount increased redemptions in a coffee campaign

Nov 20, 2026

Ad platforms can target likely buyers without creating the most extra sales

Nov 20, 2026

Sales contests worked better when employees competed in comparable groups

Nov 20, 2026

Social discounts encouraged existing grocery customers to buy more in an experiment

Nov 20, 2026

Free shipping and returns brought more shoppers back in a retail experiment

Nov 20, 2026